The ‘Forever Chemicals’ Crisis: What Healthcare Providers Need to Know About PFAS

Because PFAS are present in contaminated drinking water, food sources, and common household items, nearly everyone has some level of exposure—making it a widespread but often overlooked health risk.

Per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a growing public health concern due to their widespread use and persistence in the environment and the human body. These synthetic chemicals, first developed in the 1940s, are found in countless everyday products, from nonstick cookware and food packaging to firefighting foam and stain-resistant fabrics. Their unique chemical structure makes them highly resistant to degradation, allowing them to accumulate in soil, water, and even human tissues over time.

The persistence and bioaccumulative nature of PFAS have raised significant concerns among researchers and healthcare providers. Studies have linked prolonged exposure to various health risks. Because PFAS are present in contaminated drinking water, food sources, and common household items, nearly everyone has some level of exposure—making it a widespread but often overlooked health risk.

For healthcare providers, understanding the potential health effects of PFAS is crucial. While research is still evolving, clinicians need to be aware of the symptoms associated with PFAS exposure, the populations at highest risk, and emerging recommendations for screening and patient counseling. This blog will explore the health risks of PFAS, what clinicians should watch for, and how the medical community can respond to this growing crisis.

Understanding PFAS and Their Ubiquity

PFAS have earned the nickname “forever chemicals” because they do not break down easily in the environment or the human body. Their unique chemical structure—consisting of strong carbon-fluorine bonds—makes them highly resistant to degradation, meaning they can remain in water, soil, and living organisms for years if not decades.

Once PFAS enter the human body, they accumulate in the bloodstream, organs, and tissues, often building up over time with repeated exposure. Studies have shown that over 97% of Americans have detectable levels of PFAS in their blood, highlighting the pervasive nature of these chemicals. Given their persistence, even small amounts of exposure over time can contribute to long-term health risks.

Sources of Exposure

Because PFAS are so widely used and resistant to breakdown, exposure is nearly unavoidable. However, certain populations are at higher risk, particularly those living near industrial sites, military bases, and airports where PFAS-containing firefighting foams have been used. Common sources of exposure include:

Contaminated Drinking Water

• PFAS have been detected in municipal and private water supplies, especially near manufacturing plants and military sites.
• Communities with known contamination have reported higher-than-average rates of PFAS-related health issues.

Consumer Goods

• Nonstick cookware (e.g., Teflon-coated pans).
• Stain-resistant furniture, carpets, and waterproof clothing.
• Grease-resistant food packaging (e.g., fast-food wrappers, microwave popcorn bags).

Occupational Exposure

• Firefighters, chemical plant workers, and military personnel have higher PFAS exposure due to the use of firefighting foams and industrial chemicals.
• Factory workers in industries that manufacture PFAS-containing products may have significantly higher blood levels of these chemicals.

Food Sources

• Fish and seafood from contaminated waterways.
• Dairy and meat products from animals exposed to PFAS-contaminated water and soil.
• Produce grown in contaminated soil near industrial sites.

Given the widespread presence of PFAS, healthcare providers must recognize the potential sources of exposure when evaluating patients with unexplained chronic conditions or metabolic imbalances. Awareness of PFAS-related health risks can help clinicians provide better screening, patient education, and risk reduction strategies.

Health Risks Associated with PFAS Exposure

Growing evidence suggests that long-term exposure to PFAS chemicals can have serious health consequences. Because these substances accumulate in the body over time, even low levels of chronic exposure may increase the risk of cancer, metabolic disorders, immune dysfunction, and reproductive issues. While research is still evolving, multiple studies have linked PFAS to a range of chronic diseases, making it crucial for healthcare providers to recognize potential health effects in exposed populations.

Cancer Risk

One of the most concerning health risks associated with PFAS exposure is its link to cancer development. The strongest evidence connects PFAS exposure to kidney and testicular cancer, as documented in studies of highly exposed populations, such as those living near contaminated water sources. Additional research suggests possible links to:

• Breast cancer: PFAS may act as endocrine disruptors, altering hormone regulation in ways that could contribute to breast cancer risk.
• Liver cancer: PFAS are known to cause liver toxicity, and recent findings suggest they may play a role in liver cancer development by promoting chronic inflammation and metabolic dysfunction.

Metabolic and Endocrine Disruption

PFAS have been shown to interfere with hormone regulation and metabolism, leading to an increased risk of metabolic disorders such as:

• Obesity and insulin resistance: Research suggests that PFAS disrupts normal metabolic processes, increasing the risk of weight gain, insulin resistance, and Type 2 diabetes.
• Thyroid dysfunction: PFAS exposure has been associated with lower thyroid hormone levels, which can lead to hypothyroidism, fatigue, weight gain, and developmental issues in children.
• Altered lipid metabolism: Many studies have found that PFAS exposure correlates with higher cholesterol levels, even in young individuals with no other risk factors.

Immune System Dysfunction

Emerging research highlights the negative impact of PFAS on immune system function, particularly in children and vulnerable populations:

• Reduced vaccine effectiveness: Studies have found that children with higher PFAS levels have a weaker immune response to vaccines, including diphtheria, tetanus, and COVID-19 shots.
• Increased susceptibility to infections: PFAS exposure may impair white blood cell function, making individuals more vulnerable to viral and bacterial infections.

Cardiovascular Health Impacts

PFAS exposure has been associated with heart disease risk factors, including:

• Hypertension: Studies indicate that individuals with high PFAS exposure are at greater risk of developing high blood pressure, even in young and otherwise healthy populations.
• Increased cholesterol levels: PFAS have been linked to higher LDL (“bad” cholesterol) levels, which contribute to atherosclerosis and cardiovascular disease.

Reproductive and Developmental Effects

PFAS exposure is particularly concerning for pregnant women and developing fetuses, as these chemicals cross the placenta and have been detected in umbilical cord blood. Health risks include:

• Pregnancy complications: Higher PFAS levels have been associated with an increased risk of preeclampsia, gestational hypertension, and preterm birth.
• Low birth weight: Babies born to mothers with elevated PFAS exposure may have lower birth weights, which can impact early development and long-term health.
• Delayed puberty and reproductive issues: PFAS may interfere with hormonal development, potentially leading to delayed puberty in adolescents and reduced fertility.

The Need for Early Detection and Intervention

Given the wide-ranging health impacts of PFAS exposure, healthcare providers must stay informed and consider environmental exposures when evaluating patients with unexplained metabolic, immune, or reproductive issues. While routine PFAS screening is not yet standard in clinical practice, recognizing high-risk populations and early warning signs can help providers guide patients toward lifestyle modifications and risk reduction strategies.

What Clinicians Should Watch For

As research on PFAS exposure continues to evolve, healthcare providers play a crucial role in recognizing potential health effects, identifying at-risk patients, and offering guidance on reducing exposure. While PFAS-related illnesses can be difficult to diagnose due to their wide-ranging symptoms and long latency periods, providers should remain vigilant when evaluating unexplained chronic conditions in their patients.

Recognizing Signs of PFAS-Related Health Issues

Because PFAS accumulate in the body over time, their effects often span multiple organ systems, making diagnosis challenging. Clinicians should consider PFAS exposure in patients presenting with:

Unexplained high cholesterol or metabolic dysfunction

• • Elevated LDL cholesterol levels, even in patients with no dietary or genetic risk factors.
  • Signs of insulin resistance, unexplained weight gain, or early-onset Type 2 diabetes.

Endocrine and hormonal imbalances

• • Symptoms of hypothyroidism (fatigue, weight gain, cold intolerance) without an obvious cause.
  • Irregular menstrual cycles or fertility issues, particularly in younger patients.

Recurrent infections or weakened immune response

• • Children with reduced vaccine efficacy, particularly for tetanus and diphtheria.
  • Increased frequency of viral and bacterial infections, potentially indicating immune suppression.

Multiple unexplained symptoms spanning different organ systems

• • Patients report a mix of metabolic, immune, reproductive, and cardiovascular symptoms with no clear diagnosis.
  • History of living near contaminated sites or working in high-risk occupations.

Screening and Testing for PFAS Exposure

While routine PFAS screening is not yet standard practice, it may be appropriate for high-risk patients, including:

Individuals with known exposure

• • Those living in areas with documented PFAS water contamination.
  • Firefighters, factory workers, and military personnel who have been occupationally exposed.

Patients with persistent, unexplained chronic conditions

• • Those experiencing metabolic dysfunction, immune disorders, or hormonal imbalances without a clear underlying cause.

Pregnant women concerned about environmental exposures

• • Expecting mothers in high-risk geographic areas may benefit from discussions on exposure reduction.

Although blood testing for PFAS is available, it is primarily used in research studies and legal cases, rather than routine clinical care. Testing may confirm elevated PFAS levels, but there are currently no established treatment protocols for reducing PFAS burden in the body. Instead, healthcare providers should focus on risk reduction strategies and long-term monitoring of at-risk patients.

Patient Counseling and Risk Reduction

While eliminating PFAS exposure is difficult, clinicians can educate patients on practical ways to reduce their exposure and mitigate long-term health risks:

Filter drinking water

• • Recommend reverse osmosis or activated carbon filters, which are proven to remove PFAS from water supplies.

Avoid PFAS-containing consumer products

• • Encourage nonstick cookware alternatives, such as stainless steel or cast iron.
  • Advise against microwave popcorn, fast-food wrappers, and grease-resistant packaging.
  • Suggest PFAS-free personal care products, including some waterproof cosmetics.

Lifestyle modifications to support long-term health

• • A balanced diet rich in antioxidants may help mitigate oxidative stress linked to PFAS exposure.
  • Encourage regular monitoring of cholesterol, liver function, and thyroid health in at-risk patients.

Stay informed about emerging medical guidelines and regulations

• • Healthcare providers should keep up with evolving PFAS research, regulatory policies, and patient safety recommendations.
  • Encourage patient advocacy for stronger environmental protections and safer manufacturing practices.

By recognizing early warning signs, guiding patients toward exposure reduction, and staying informed on the latest medical research, clinicians can play a proactive role in addressing the health impacts of PFAS. While there is still much to learn about these “forever chemicals,” healthcare providers can help mitigate risks and improve patient outcomes through education and prevention strategies.

The Future of PFAS Research and Healthcare Response

As awareness of PFAS-related health risks grows, researchers, policymakers, and healthcare providers are working toward mitigating exposure, improving patient care, and advocating for regulatory changes. The next decade will be critical in shaping how the medical community understands, monitors, and manages PFAS-related health conditions.

Regulatory and Policy Changes

Regulatory agencies worldwide are taking action to limit PFAS contamination and reduce human exposure. In the U.S., the Environmental Protection Agency (EPA) has introduced new drinking water limits for PFAS and is holding manufacturers accountable for pollution. Key regulatory developments include:

Stricter PFAS drinking water standards

• • In 2023, the EPA proposed the first-ever federal drinking water limits for six PFAS compounds, aiming to protect millions of Americans from contaminated water.
  • Many states have already adopted even stricter guidelines, particularly in areas with high contamination levels.

Legal actions against PFAS manufacturers

• • Major chemical companies, including 3M and DuPont, have faced lawsuits for PFAS contamination and are settling multi-billion-dollar claims to fund water treatment initiatives.
  • These legal precedents could pave the way for increased corporate accountability in environmental health.

Phasing out PFAS in consumer goods and industrial processes

• • The European Union is considering a complete PFAS ban in non-essential products.
  • Many brands have voluntarily removed PFAS from food packaging, personal care items, and textiles, signaling a shift toward safer alternatives.

These regulations mark progress, but PFAS remain persistent pollutants, making medical research and healthcare advocacy essential in protecting public health.

Medical Advancements and Research

While no current treatment exists to remove PFAS from the body, researchers are exploring strategies to accelerate detoxification and reduce bioaccumulation. Some emerging areas of study include:

PFAS detoxification strategies

• • Scientists are investigating whether certain dietary interventions (e.g., high-fiber diets, chelation therapy, or bile acid sequestrants) could help the body excrete PFAS more efficiently.
  • Experimental drug therapies aim to bind and remove PFAS compounds, but these are still in early testing stages.

Pharmacological interventions to mitigate PFAS effects

• • Some studies suggest that statins and thyroid medications may help counteract the metabolic and endocrine disruptions caused by PFAS.
  • Research into antioxidant therapies and liver-protective agents is ongoing.

Long-term health monitoring for exposed populations

• • Large-scale studies are tracking PFAS-exposed communities to assess cancer rates, immune function, and metabolic changes over time.
  • Biomonitoring programs are helping identify which subpopulations face the highest risks and guiding personalized prevention efforts.

Protecting Patients from the Risks of PFAS Exposure

PFAS, or “forever chemicals,” have become a growing public health concern, with mounting evidence linking them to cancer, metabolic disorders, immune dysfunction, and reproductive issues. Their persistence in the environment and human body makes them a unique and long-term health threat, requiring increased awareness among healthcare providers. Given that exposure is widespread and often goes unnoticed, clinicians must proactively recognize symptoms, educate patients, and advocate for stronger environmental protections.

Early recognition of PFAS-related health effects can help mitigate long-term complications. While routine testing is not yet standard, identifying high-risk patients, monitoring for unexplained metabolic or immune dysfunction, and guiding patients toward exposure reduction strategies can make a meaningful difference. Healthcare providers should also stay informed on emerging research, regulatory updates, and medical advancements to better support affected patients and communities.

Addressing PFAS exposure is more than just a public health challenge—it’s about protecting current and future generations from preventable harm. As research continues, healthcare professionals have a crucial role in ensuring that patients receive the guidance, screening, and education they need to reduce their risks. By staying informed and advocating for stronger protections and medical interventions, clinicians can help drive change in both patient care and public health policy.

“Understanding the risks of PFAS exposure isn’t just about public health—it’s about protecting our patients and future generations from long-term harm.”

References

Ayodele, A., & Obeng-Gyasi, E. (2024). Exploring the potential link between PFAS exposure and endometrial cancer: A review of environmental and sociodemographic factors. Cancers, 16(5), 983. https://doi.org/10.3390/cancers16050983

Bailey, J. M., Wang, L., McDonald, J. M., Gray, J. S., Petrie, J. G., Martin, E. T., Savitz, D. A., Karrer, T. A., Fisher, K. A., Geiger, M. J., & Wasilevich, E. A. (2023). Immune response to COVID-19 vaccination in a population with a history of elevated exposure to per- and polyfluoroalkyl substances (PFAS) through drinking water. Journal of Exposure Science & Environmental Epidemiology, 33(5), 725–736. https://doi.org/10.1038/s41370-023-00564-8

Barrett, E. S., & Rivera-Núñez, Z. (2023). Invited perspective: PFAS and pubertal timing in girls—a maturing literature. Environmental Health Perspectives, 131(9), 91304. https://doi.org/10.1289/EHP12658

Coperchini, F., Croce, L., Ricci, G., Magri, F., Rotondi, M., Imbriani, M., & Chiovato, L. (2021). Thyroid disrupting effects of old and new generation PFAS. Frontiers in Endocrinology, 11, 612320. https://doi.org/10.3389/fendo.2020.612320

Dimitrakopoulou, M. E., Karvounis, M., Marinos, G., et al. (2024). Comprehensive analysis of PFAS presence from environment to plate. npj Science of Food, 8, Article 80. https://doi.org/10.1038/s41538-024-00319-1

Du, X., Wu, Y., Tao, G., Xu, J., Du, Z., Wu, M., Gu, T., Xiong, J., Xiao, S., Wei, X., Ruan, Y., Xiao, P., Zhang, L., & Zheng, W. (2024). Association between PFAS exposure and thyroid health: A systematic review and meta-analysis for adolescents, pregnant women, adults, and toxicological evidence. Science of the Total Environment, 953, 175958. https://doi.org/10.1016/j.scitotenv.2024.175958

Fenton, S. E., Ducatman, A., Boobis, A., DeWitt, J. C., Lau, C., Ng, C., Smith, J. S., & Roberts, S. M. (2021). Per- and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research. Environmental Toxicology and Chemistry, 40(3), 606–630. Retrieved February 12, 2025, from https://doi.org/10.1002/etc.4890

First Environment. (n.d.). 3M and DuPont national settlements for PFAS drinking water contamination claims. Retrieved February 12, 2025, from https://www.firstenvironment.com/3m-and-dupont-national-settlements-for-pfas-drinking-water-contamination-claims

Kang, H., Ding, N., Karvonen-Gutierrez, C. A., Mukherjee, B., Calafat, A. M., & Park, S. K. (2023). Per- and polyfluoroalkyl substances (PFAS) and lipid trajectories in women 45–56 years of age: The Study of Women’s Health Across the Nation. Environmental Health Perspectives, 131(8), 87004. https://doi.org/10.1289/EHP12351

Lewis, R. C., Johns, L. E., & Meeker, J. D. (2015). Serum biomarkers of exposure to perfluoroalkyl substances in relation to serum testosterone and measures of thyroid function among adults and adolescents from NHANES 2011–2012. International Journal of Environmental Research and Public Health, 12(6), 6098–6114. https://doi.org/10.3390/ijerph120606098

Lopez-Espinosa, M. J., Carrizosa, C., Luster, M. I., Margolick, J. B., Costa, O., Leonardi, G. S., & Fletcher, T. (2021). Perfluoroalkyl substances and immune cell counts in adults from the Mid-Ohio Valley (USA). Environment International, 156, 106599. https://doi.org/10.1016/j.envint.2021.106599

Ma, G., & Ducatman, A. (2022). Perfluoroalkyl substance serum concentrations and cholesterol absorption-inhibiting medication ezetimibe. Toxics, 10(12), 799. https://doi.org/10.3390/toxics10120799

Pitter, G., Zare Jeddi, M., Barbieri, G., Gion, M., Fabricio, A. S. C., Daprà, F., Russo, F., Fletcher, T., & Canova, C. (2020). Perfluoroalkyl substances are associated with elevated blood pressure and hypertension in highly exposed young adults. Environmental Health, 19(1), 102. https://doi.org/10.1186/s12940-020-00656-0

PFAS Water Experts. (n.d.). PFAS contamination in water sources. Retrieved February 12, 2025, from https://pfaswaterexperts.org/pfas-water-contamination/

Reuters. (2025, January 20). EU plans ban of ‘forever chemicals’ in consumer products. Retrieved February 12, 2025, from https://www.reuters.com/business/environment/eu-plans-ban-forever-chemicals-consumer-products-2025-01-20/

Sen, P., Fan, Y., Schlezinger, J. J., Ehrlich, S. D., Webster, T. F., Hyötyläinen, T., Pedersen, O., & Orešič, M. (2024). Exposure to environmental toxicants is associated with gut microbiome dysbiosis, insulin resistance and obesity. Environment International, 186, 108569. https://doi.org/10.1016/j.envint.2024.108569

Taibl, K. R., Schantz, S., Aung, M. T., Padula, A., Geiger, S., Smith, S., Park, J.-S., Milne, G. L., Robinson, J. F., Woodruff, T. J., Morello-Frosch, R., & Eick, S. M. (2022). Associations of per- and polyfluoroalkyl substances (PFAS) and their mixture with oxidative stress biomarkers during pregnancy. Environment International, 169, 107541. https://doi.org/10.1016/j.envint.2022.107541

U.S. Environmental Protection Agency. (n.d.). Per- and polyfluoroalkyl substances (PFAS). Retrieved February 12, 2025, from https://www.epa.gov/sdwa/and-polyfluoroalkyl-substances-pfas

U.S. Environmental Protection Agency. (n.d.). Reducing PFAS in drinking water with treatment technologies. Retrieved February 12, 2025, from https://www.epa.gov/sciencematters/reducing-pfas-drinking-water-treatment-technologies

U.S. Food and Drug Administration. (n.d.). Per- and polyfluoroalkyl substances (PFAS). Retrieved February 12, 2025, from https://www.fda.gov/food/environmental-contaminants-food/and-polyfluoroalkyl-substances-pfas

Verner, M. A., Loccisano, A. E., Morken, N. H., Yoon, M., Wu, H., McDougall, R., Maisonet, M., Marcus, M., Kishi, R., Miyashita, C., Chen, M. H., Hsieh, W. S., Andersen, M. E., Clewell, H. J., 3rd, & Longnecker, M. P. (2015). Associations of perfluoroalkyl substances (PFAS) with lower birth weight: An evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK). Environmental Health Perspectives, 123(12), 1317–1324. https://doi.org/10.1289/ehp.1408837

Wee, S. Y., & Aris, A. Z. (2023). Environmental impacts, exposure pathways, and health effects of PFOA and PFOS. Ecotoxicology and Environmental Safety, 267, 115663. https://doi.org/10.1016/j.ecoenv.2023.115663

Wikström, S., Lindh, C. H., Shu, H., et al. (2019). Early pregnancy serum levels of perfluoroalkyl substances and risk of preeclampsia in Swedish women. Scientific Reports, 9, Article 9179. https://doi.org/10.1038/s41598-019-45483-7

Zheng, J., Liu, S., Yang, J., Zheng, S., & Sun, B. (2024). Per- and polyfluoroalkyl substances (PFAS) and cancer: Detection methodologies, epidemiological insights, potential carcinogenic mechanisms, and future perspectives. Science of the Total Environment, 953, 176158. https://doi.org/10.1016/j.scitotenv.2024.176158